Tas-205 (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 113 | 筋ジストロフィー | 3 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04587908 (ClinicalTrials.gov) | November 2020 | 13/10/2020 | A Phase 3 Study of TAS-205 in Patients With Duchenne Muscular Dystrophy(REACH-DMD) | A Phase 3, Randomized, Placebo-controlled, Double-blind and Open-label, Extension Study of TAS-205 in Patients With Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy | Drug: TAS-205;Drug: Placebo | Taiho Pharmaceutical Co., Ltd. | NULL | Not yet recruiting | 5 Years | N/A | Male | 80 | Phase 3 | Japan |
| 2 | NCT02752048 (ClinicalTrials.gov) | May 2016 | 6/4/2016 | A Phase IIa Study of TAS-205 for Duchenne Muscular Dystrophy | A Randomized Phase IIa Study of TAS-205 in Patients With Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy | Drug: TAS-205;Drug: Placebo | Taiho Pharmaceutical Co., Ltd. | NULL | Completed | 5 Years | N/A | Male | 36 | Phase 2 | Japan |
| 3 | NCT02246478 (ClinicalTrials.gov) | September 2014 | 9/9/2014 | A Study of TAS-205 for Duchenne Muscular Dystrophy | A Phase I Study of Single and Multiple Doses of TAS-205 in Patients With Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy | Drug: TAS-205;Drug: Placebo | Taiho Pharmaceutical Co., Ltd. | NULL | Completed | 5 Years | 15 Years | Male | 21 | Phase 1 | Japan |